UltraSPECT to Present Xpress Suite of
Safer Imaging Solutions at SNMMI 2015
SNMMI Attendees Invited to Take Part in New “Hot Trot 5K” Run/Walk to Benefit
Professional Development of Nuclear Medicine Technologists
Auburndale, Mass., June 1, 2015 (SNMMI Booth #517) – UltraSPECT, a provider of the most cost-effective and vendor-neutral low dose and ultra-low-dose nuclear medicine imaging solutions, will present its Xpress suite of value packages at booth #517 during the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting from June 6-10 in Baltimore, MD. Low dose imaging increases safety for patients and technologists while providing physicians with high-quality images for accurate diagnosis.
At the UltraSPECT booth, the SNMMI attendees will learn about how Xpress.Cardiac™, Xpress3.Cardiac™ and Xpress/Xact.Bone™ solutions can provide value to physicians, technologists, patients, administrators and radiopharmaceutical suppliers. Whether imaging at half or quarter time or simultaneously at half dose and half time, physicians will have images as good, if not better, than those provided with traditional SPECT acquisition due to UltraSPECT’s exclusive reconstruction algorithms. With low dose imaging, technologists will benefit from safer and shorter scans, increasing patient comfort, and may also be able to increase the patient throughput in a laboratory without changes in the existing workflow.
At a fraction of the cost – five to 10 percent – of a brand new camera, UltraSPECT allows healthcare organizations comply with the American Society of Nuclear Cardiology (ASNC) 2014 dose-reduction guidelines in a cost-effective manner.
“The initiative to lower the dose is driven by the industry looking for a safer and more cost-effective way to serve patients, who, in their turn, become increasingly sophisticated when it comes to medical solutions proposed to them,” said Yossi Srour, President and CEO, UltraSPECT. “They request lower dose, and we are pleased to offer a safer imaging solution that answers the needs of all in this process.”
New This Year -- “Hot Trot 5K” Run/Walk
Additionally, UltraSPECT invites attendees to take part in the SNMMI’s new “Hot Trot 5K” run/walk, for which it provided the gold-level sponsorship to support the SNMMI-TS Professional Development and Education Fund. The Fund furthers professional advancement of molecular and nuclear medicine technologists to promote clinical excellence and optimal patient outcomes. Additionally, a portion of the registration proceeds will support a local charity, House of Ruth Maryland. The event is scheduled for Saturday, June 6, at 7:30 a.m. To learn more and sign up, visit the SNMMI 5K registration page.
“The run and walk event is a great addition to the SNMMI program and we encourage everyone who can join to take part not just for the camaraderie and exercise, but to support programs that allow technologists to advance their careers while strengthening our industry,” said Srour.
More than 450 UltraSPECT nuclear medicine units have been installed in over 300 health systems across the country, including St. Luke’s-Roosevelt Hospital in New York City, Mayo Clinic in Rochester, MN, Duke University Medical Center in Durham, NC, Henry Ford Wyandotte Hospital in Wyandotte, Mich., and multiple Maine Health facilities throughout the state.
For more information on the UltraSPECT technologies and reducing dose in nuclear medicine, visit www.ultraspect.com or call 1-888-WBR-SCAN (1-888-927-7226). To schedule an appointment to meet with the company during the SNMMI, contact Yossi Srour at yossi.srour@ULTRASPECT.COM.
UltraSPECT Inc. is the only provider of image reconstruction solutions that can simultaneously lower radiation dose, shorten acquisition times and increase diagnostic quality for any nuclear medicine exam. Based on proprietary, innovative Wide-Beam Reconstruction (WBR™) algorithms, UltraSPECT products continue to be the most cost-effective dose-reduction solutions available. Healthcare facilities of all sizes maximize value from the ability to leverage the investment in existing nuclear medicine cameras – regardless of the manufacturer, model and age. Moreover, UltraSPECT solutions enable healthcare facilities to meet the American Society of Nuclear Cardiology (ASNC) low-dose guidelines. UltraSPECT image reconstruction products are approved by the FDA, as well as numerous regulatory authorities in Europe and Asia, and are in routine clinical use in hundreds of leading nuclear medicine imaging centers around the world. For more information, visit https://ultraspect.com.
# # #
Courtney Kraemer, KNB Communications for UltraSPECT